ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Want to see ABVC full AI Analyst Report?
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.88 - $5.48
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$33.54M
Enterprise Value$19.11M
Total Cash (Recent Filing)$202.51K
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding26,000,443
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue-24.01
Enterprise Value/Gross Profit-21.52
Enterprise Value/Ebitda-2.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Board Stability & Equity Incentive PlanRe-election of the full board and an expanded equity incentive plan supports leadership continuity and talent retention critical for multi-year clinical programs. Equity incentives align management to long-term milestones and partnering outcomes, strengthening execution capacity despite dilution tradeoffs.
Moderate Leverage And Asset BaseDebt at roughly 0.31x equity and an equity cushion supporting ~ $20M in assets imply moderate leverage versus peers, giving the company some balance sheet flexibility. This reduces immediate solvency risk and preserves optionality to fund R&D or secure partnerships over the next several quarters.
Improving Cash Burn TrendMaterial reduction in operating cash outflows in the TTM period indicates improving cash management or timing of spend and receipts. While still negative, a lower burn lessens near-term financing pressure, making it easier to sustain clinical progress and pursue partnering milestones without immediate dilution.
Bears Say
Persistent UnprofitabilityConsistent multi-year net losses and structurally negative margins erode equity and constrain reinvestment. For a clinical-stage biopharma with no commercial product, persistent unprofitability means continued reliance on external capital and increased execution risk if funding markets tighten.
Weak Cash Generation & Negative Free Cash FlowChronic negative operating and free cash flow prevents internal self-funding of trials and forces regular access to capital markets or partners. This elevates dilution and execution risk, as program timelines and development choices can be constrained by financing availability rather than scientific priorities.
Tiny Revenue Base; No Commercial ProductsWith virtually no recurring product revenue and reliance on out-licensing or milestone receipts, the company lacks predictable cash streams. Long lead times to commercialization make funding and partner-dependent monetization structural limits to sustainable margins and predictable growth.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.88 and its highest was $5.48 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $33.54M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 171 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Mar 27, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 26,000,443 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.66%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ABVC BioPharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
447.44%
12-Months-Change
Fundamentals
Return on Equity
-70.28%
Trailing 12-Months
Asset Growth
32.65%
Trailing 12-Months
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.40% Mutual Funds
0.04% Other Institutional Investors
97.83% Public Companies and
Individual Investors